Abstract: Use of cyclosporin H (CsH) or a derivative thereof for increasing the efficiency of transduction of an isolated population of cells by a viral vector and/or increasing the efficiency of gene editing of an isolated population of cells when transduced by a viral vector.

Abstract: A gene vector for use in gene therapy comprising at least one miRNA sequence target operably linked to a nucleotide sequence having a corresponding miRNA in a hematopoietic progenitor cell (HSPC) or hematopoietic stem cell (HSC) which prevents or reduces expression of the nucleotide sequence in a HSPC or HSC but not in a differentiated cell.

Abstract: A gene vector for use in gene therapy comprising at least one miRNA sequence target operably linked to a nucleotide sequence having a corresponding miRNA in a hematopoietic progenitor cell (HSPC) or hematopoietic stem cell (HSC) which prevents or reduces expression of the nucleotide sequence in a HSPC or HSC but not in a differentiated cell.

Abstract: Use of cyclosporin H (CsH) or a derivative thereof for increasing the efficiency of transduction of an isolated population of cells by a viral vector and/or increasing the efficiency of gene editing of an isolated population of cells when transduced by a viral vector.

Abstract: A method of preparing a therapeutic cell population for clinical use from a starting population of cells comprising haematopoietic stem cells, said method comprising separating a population of cells that substantially do not express CD38 but which express CD34 from the starting population of cells, and transducing the separated cell population with a vector to obtain the therapeutic cell population.

Abstract: A method of preparing a therapeutic cell population for clinical use from a starting population of cells comprising haematopoietic stem cells, said method comprising separating a population of cells that substantially do not express CD38 but which express CD34 from the starting population of cells, and transducing the separated cell population with a vector to obtain the therapeutic cell population.

Abstract: A hematopoietic stem cell (HSC), a hematopoietic progenitor cell (HPC) a myeloid/monocyte-committed progenitor cell, a macrophage or a monocyte comprising a vector wherein the vector comprises at least one mir-130a and/or mir-126 target sequence operably linked to a nucleotide sequence encoding interferon-alpha (IFN?) for use in treating or preventing a cancer in a patient, wherein the HSC, the HPC, the myeloid/monocyte-committed progenitor cell, the macrophage or the monocyte is used in combination with an immune checkpoint inhibitor and/or a tumor associated antigen (TAA)-specific T-cell.

Abstract: A gene vector for use in gene therapy comprising at least one miRNA sequence target operably linked to a nucleotide sequence having a corresponding miRNA in a hematopoietic progenitor cell (HSPC) or hematopoietic stem cell (HSC) which prevents or reduces expression of the nucleotide sequence in a HSPC or HSC but not in a differentiated cell.

Abstract: A gene vector for use in gene therapy comprising at least one miRNA sequence target operably linked to a nucleotide sequence having a corresponding miRNA in a hematopoietic progenitor cell (HSPC) or hematopoietic stem cell (HSC) which prevents or reduces expression of the nucleotide sequence in a HSPC or HSC but not in a differentiated cell.

Abstract: A gene vector for use in gene therapy comprising at least one miRNA sequence target operably linked to a nucleotide sequence having a corresponding miRNA in a hematopoietic progenitor cell (HSPC) or hematopoietic stem cell (HSC) which prevents or reduces expression of the nucleotide sequence in a HSPC or HSC but not in a differentiated cell.

Abstract: A gene vector for use in gene therapy comprising at least one miRNA sequence target operably linked to a nucleotide sequence having a corresponding miRNA in a hematopoietic progenitor cell (HSPC) or hematopoietic stem cell (HSC) which prevents or reduces expression of the nucleotide sequence in a HSPC or HSC but not in a differentiated cell.

Abstract: A method of preparing a therapeutic cell population for clinical use from a starting population of cells comprising haematopoietic stem cells, said method comprising separating a population of cells that substantially do not express CD38 but which express CD34 from the starting population of cells, and transducing the separated cell population with a vector to obtain the therapeutic cell population.

Abstract: Methods, systems, and apparatus, including computer program products, for implementing a software architecture design for a software application implementing selling standardized services. The application is structured as multiple process components interacting with each other through service interfaces, and multiple service operations, each being implemented for a respective process component. The process components include a Customer Quote Processing process component; a Sales Order Processing process component; a Service Confirmation Processing process component; a Financial Accounting Master Data Management processing component; a Customer Invoice Processing process component; an Accounting process component; a Balance of Foreign Payment Management process component; a Due Item Processing process component; and a Payment Processing process component.

Abstract: A business object model, which reflects data that is used during a given business transaction, is utilized to generate interfaces. This business object model facilitates commercial transactions by providing consistent interfaces that are suitable for use across industries, across businesses, and across different departments within a business during a business transaction. In some operations, software creates, updates, or otherwise processes information related to a cost object settlement rule and an inventory notification business object.

Abstract: Systems and methods to provide integration of partner ERP systems into a host financial system using generic cost objects. In example embodiments, an accounting system having a generic cost object is maintained. A user interface for creating a configured cost object that represents a specialized business item is provided. Data that mirrors the configured cost object is received, which results in a mirror cost object. Accounting operations are performed in the accounting system based on the mirror cost object and a corresponding business control set by replacing the generic cost object with the mirror cost object. Output based on performance of the accounting operations based on the mirror cost object and corresponding business configuration set are provided.

Abstract: A gene vector for use in gene therapy comprising at least one miRNA sequence target operably linked to a nucleotide sequence having a corresponding miRNA in a hematopoietic progenitor cell (HSPC) or hematopoietic stem cell (HSC) which prevents or reduces expression of the nucleotide sequence in a HSPC or HSC but not in a differentiated cell.

Abstract: Methods, systems, and apparatus, including computer program products, for implementing a software architecture design for a software application implementing selling standardized services. The application is structured as multiple process components interacting with each other through service interfaces, and multiple service operations, each being implemented for a respective process component. The process components include a Customer Quote Processing process component; a Sales Order Processing process component; a Service Confirmation Processing process component; a Financial Accounting Master Data Management processing component; a Customer Invoice Processing process component; an Accounting process component; a Balance of Foreign Payment Management process component; a Due Item Processing process component; and a Payment Processing process component.

Abstract: In some embodiments, a method includes: generating entries for at least one cost plan, each of the entries including a planned amount and a descriptor, wherein the descriptor identifies a general ledger account. In some embodiments, a method includes: generating postings for at least one ledger, each of the postings including an actual amount, a first descriptor and a second descriptor, wherein the first descriptor identifies a general ledger account and wherein the second descriptor identifies a general ledger account.

Abstract: In some embodiments, a method includes: generating entries for at least one cost plan, each of the entries including a planned amount and a descriptor, wherein the descriptor identifies a general ledger account. In some embodiments, a method includes: generating postings for at least one ledger, each of the postings including an actual amount, a first descriptor and a second descriptor, wherein the first descriptor identifies a general ledger account and wherein the second descriptor identifies a general ledger account.